DiscoveryProbe™ FDA-approved Drug Library: A Benchmark Resource for High-Throughput Drug Screening

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) contains 2,320 bioactive compounds, each clinically approved or pharmacopeia-listed by agencies such as the FDA, EMA, HMA, CFDA, and PMDA (DiscoveryProbe™ FDA-approved Drug Library). This resource is engineered for high-throughput and high-content screening, supporting drug repositioning and target identification across a wide spectrum of disease models (see prior review). Compounds are supplied as 10 mM DMSO solutions, stable up to 24 months at -80°C. The library encompasses a wide range of mechanisms, including receptor agonists/antagonists, enzyme inhibitors, and signal pathway modulators. Recent studies validate the utility of such libraries for identifying novel disease-modifying drug candidates, such as 5-aminosalicylic acid for osteoarthritis (Kim et al., 2024).

Biological Rationale

High-throughput screening (HTS) platforms require access to chemically diverse, well-characterized compounds to identify modulators of biological targets efficiently. The DiscoveryProbe™ FDA-approved Drug Library addresses this need by providing a ready-to-screen, regulatory-vetted set of small molecules. FDA- and EMA-approved drugs have established clinical safety and pharmacokinetics, making them ideal candidates for drug repositioning and rapid preclinical development. Furthermore, the inclusion of compounds with known mechanisms, such as doxorubicin (DNA intercalator), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor), enables mechanistic dissection of cellular pathways in cancer, metabolic, and neurodegenerative disease models (related analysis). The use of pre-dissolved 10 mM DMSO stocks ensures compatibility with automated liquid handling and minimizes compound loss or degradation during screening workflows.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ library comprises compounds targeting a broad array of biological processes. Mechanisms of action include:

• Receptor agonists and antagonists: Modulate G protein-coupled receptors, nuclear receptors, and ligand-gated ion channels.
• Enzyme inhibitors: Inhibit kinases, phosphatases, proteases, and metabolic enzymes (e.g., metformin inhibits mitochondrial complex I).
• Ion channel modulators: Affect calcium, sodium, and potassium channel activity in neuronal and cardiac models.
• Signal pathway regulators: Disrupt or enhance intracellular signaling, such as the mTOR, MAPK, or PPARγ pathways.

This mechanistic diversity enables the interrogation of complex disease phenotypes and the discovery of pharmacological probes that modulate previously 'undruggable' targets (further discussion).

Evidence & Benchmarks

• Screening of 3,287 compounds—including FDA-approved drugs—identified 5-aminosalicylic acid (5-ASA) as a disease-modifying osteoarthritis drug candidate (Kim et al., 2024, DOI:10.1038/s41467-024-45174-6).
• 5-ASA demonstrated efficacy in vivo: intra-articular injections in mice with surgically induced osteoarthritis resulted in statistically significant cartilage preservation at 12 weeks (Kim et al., 2024, DOI:10.1038/s41467-024-45174-6).
• The DiscoveryProbe™ FDA-approved Drug Library supports both high-throughput (HTS) and high-content screening (HCS) modalities, enabling rapid phenotypic and mechanistic drug screening (product data).
• Compounds are stable for 12 months at -20°C and up to 24 months at -80°C, supporting long-term, reproducible screening campaigns (product documentation).
• Repositioning of known drugs has led to the identification of new therapeutic uses, validated in oncology, neurodegeneration, and inflammatory diseases (prior workflow study).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is used in:

• Drug repositioning screens to identify new indications for approved drugs.
• Target identification and validation studies in cancer, neurodegeneration, and rare diseases.
• Mechanistic studies of signaling and metabolic pathways.
• Phenotypic screens using cell-based assays or disease models.

However, there are important boundaries to its utility.

Common Pitfalls or Misconceptions

• The library is not a substitute for de novo chemical diversity screens: All compounds are clinically approved or pharmacopeia-listed, so novel chemical space is limited.
• Not all disease-relevant targets are represented: Some targets, especially those without approved drugs, are not covered.
• In vitro activity does not guarantee in vivo efficacy: Repositioned hits require rigorous follow-up validation.
• Compound solubility and DMSO compatibility: While pre-dissolved, some compounds may precipitate under certain assay conditions.
• Screening does not address formulation or delivery obstacles: Clinical translation requires addressing pharmacokinetics and toxicity profiles.

This article extends previous implementation workflows by providing updated evidence from recent osteoarthritis models, highlighting new disease-modifying candidates discovered via library screening. It also clarifies the mechanistic breadth described in earlier mechanistic analyses.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is supplied as 10 mM DMSO solutions in 96-well microplates, deep-well plates, or 2D barcoded tubes. Key parameters for integration:

• Compounds are compatible with standard HTS and HCS platforms using liquid handlers calibrated for DMSO-based solutions.
• For typical primary screens, final assay concentrations range from 1–10 µM per compound; dilution protocols should account for DMSO tolerance (<1% v/v in most cell-based assays).
• Shipping is performed on blue ice for evaluation sizes and at room temperature or blue ice for larger formats, ensuring compound integrity (official guidelines).
• Long-term storage at -80°C maintains compound stability and reproducibility over multiple campaigns.
• Standardized barcoding and plate mapping facilitate automated tracking and data integration.

Best practices include routine quality checks by LC-MS or HPLC and parallel positive/negative controls to benchmark assay performance.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a validated, versatile tool for high-throughput and high-content screening, enabling rapid identification of drug repositioning candidates and mechanistic probes. Its structure—covering a spectrum of clinical mechanisms—and rigorous curation make it an ideal starting point for translational research in oncology, neurodegeneration, and beyond. Recent advances, such as identification of 5-ASA as a disease-modifying osteoarthritis agent, underscore the practical utility of such libraries (Kim et al., 2024). Future iterations may expand chemical diversity while maintaining clinical relevance, further accelerating the path from bench to bedside.